{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T02:32:23Z","timestamp":1771813943497,"version":"3.50.1"},"reference-count":140,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["GA18-01734S"],"award-info":[{"award-number":["GA18-01734S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-02\/202.961\/2017"],"award-info":[{"award-number":["E-02\/202.961\/2017"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["308225\/2018-0"],"award-info":[{"award-number":["308225\/2018-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Beyond being epiphenomenon of shared epidemiological factors, the integration of Osteoporosis\n(OP) with Cardiovascular Disease (CVD) - termed \u201ccalcification paradox\u201d - reflects a continuum\nof aberrant cardiometabolic status. The present review provides background knowledge on \u201ccalcification\nparadox\u201d, focusing on the endocrine aspect of vasculature orchestrated by the osteoblastic molecular\nfingerprint of vascular cells, acquired via imbalance among established modulators of mineralization.\nOsteoprotegerin (OPG), the well-established osteoprotective cytokine, has recently been shown to\nexert a vessel-modifying role. Prompted by this notion, the present review interrogates OPG as the\npotential missing link between OP and CVD. However, so far, the confirmation of this hypothesis is\nhindered by the equivocal role of OPG in CVD, being both proatherosclerotic and antiatherosclerotic.\nFurther research is needed to illuminate whether OPG could be a biomarker of the \u201ccalcification paradox\u201d.\nMoreover, the present review brings into prominence the dual role of statins - cardioprotective\nand osteoprotective - as a potential illustration of the integration of CVD with OP. Considering that the\nstatins-induced modulation of OPG is central to the statins-driven osteoprotective signalling, statins\ncould be suggested as an illustration of the role of OPG in the bone\/vessels crosstalk, if further studies\nconsolidate the contribution of OPG to the cardioprotective role of statins. Another outstanding issue\nthat merits further evaluation is the inconsistency of the osteoprotective role of statins. Further understanding\nof the varying bone-modifying role of statins, likely attributed to the unique profile of different\nclasses of statins defined by distinct physicochemical characteristics, may yield tangible benefits for\ntreating simultaneously OP and CVD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200123151132","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T13:30:48Z","timestamp":1579786248000},"page":"1443-1467","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-954X","authenticated-orcid":true,"given":"Maria V.","family":"Deligiorgi","sequence":"first","affiliation":[{"name":"Department of Pharmacology - Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias, 11527 Goudi, Athens,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-3552","authenticated-orcid":true,"given":"Mihalis I.","family":"Panayiotidis","sequence":"additional","affiliation":[{"name":"Department of Applied Sciences, Group of Translational Biosciences, Faculty of Health & Life Sciences, Northumbria University, Ellison Building A516, Newcastle Upon Tyne, NE1 8ST,United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-8870","authenticated-orcid":true,"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, 1st Hippokration Hospital, National and Kapodistrian University of Athens, 114 Vas Sofias, 11527 Athens,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-9780","authenticated-orcid":true,"given":"Dimitrios T.","family":"Trafalis","sequence":"additional","affiliation":[{"name":"Department of Pharmacology - Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, Building 16, 1st Floor, 75 Mikras Asias, 11527 Goudi, Athens,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare5010014","volume":"5","author":"Baird J.","year":"2017","unstructured":"Baird J.; Jacob C.; Barker M.; Fall C.H.; Hanson M.; Harvey N.C.; Inskip H.M.; Kumaran K.; Cooper C.; Developmental origins of health and disease: a lifecourse approach to the prevention of non-communicable diseases. Healthcare (Basel) 2017,5(1)","journal-title":"Healthcare (Basel)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/CIR.0b013e318282ab8f","volume":"127","author":"Go A.S.","year":"2013","unstructured":"Go A.S.; Mozaffarian D.; Roger V.L.; Benjamin E.J.; Berry J.D.; Borden W.B.; Bravata D.M.; Dai S.; Ford E.S.; Fox C.S.; Franco S.; Fullerton H.J.; Gillespie C.; Hailpern S.M.; Heit J.A.; Howard V.J.; Huffman M.D.; Kissela B.M.; Kittner S.J.; Lackland D.T.; Lichtman J.H.; Lisabeth L.D.; Magid D.; Marcus G.M.; Marelli A.; Matchar D.B.; McGuire D.K.; Mohler E.R.; Moy C.S.; Mussolino M.E.; Nichol G.; Paynter N.P.; Schreiner P.J.; Sorlie P.D.; Stein J.; Turan T.N.; Virani S.S.; Wong N.D.; Woo D.; Turner M.B.; Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013,127(1),143-152","journal-title":"Circulation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cpcardiol.2009.10.002","volume":"35","author":"Gaziano T.A.","year":"2010","unstructured":"Gaziano T.A.; Bitton A.; Anand S.; Abrahams-Gessel S.; Murphy A.; Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010,35(2),72-115","journal-title":"Curr Probl Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00223-013-9712-z","volume":"93","author":"Wu M.","year":"2013","unstructured":"Wu M.; Rementer C.; Giachelli C.M.; Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 2013,93(4),365-373","journal-title":"Calcif Tissue Int"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijotn.2017.04.004","volume":"26","author":"Curtis E.M.","year":"2017","unstructured":"Curtis E.M.; Moon R.J.; Harvey N.C.; Cooper C.; Reprint of: the impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Int J Orthop Trauma Nurs 2017,26,7-17","journal-title":"Int J Orthop Trauma Nurs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000262308","volume":"29","author":"Nordstr&#xF6;m A.","year":"2010","unstructured":"Nordstr&#xF6;m A.; Eriksson M.; Stegmayr B.; Gustafson Y.; Nordstr&#xF6;m P.; Low bone mineral density is an independent risk factor for stroke and death. Cerebrovasc Dis 2010,29(2),130-136","journal-title":"Cerebrovasc Dis"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1242\/dev.125.4.725","volume":"125","author":"Choi K.","year":"1998","unstructured":"Choi K.; Kennedy M.; Kazarov A.; Papadimitriou J.C.; Keller G.; A common precursor for hematopoietic and endothelial cells. Development 1998,125(4),725-732","journal-title":"Development"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature13146","volume":"507","author":"Ramasamy S.K.","year":"2014","unstructured":"Ramasamy S.K.; Kusumbe A.P.; Wang L.; Adams R.H.; Endothelial notch activity promotes angiogenesis and osteogenesis in bone. Nature 2014,507(7492),376-380","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molmed.2009.07.001","volume":"15","author":"Persy V.","year":"2009","unstructured":"Persy V.; D\u2019Haese P.; Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 2009,15(9),405-416","journal-title":"Trends Mol Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1385\/ENDO:23:1:01","volume":"23","author":"McFarlane S.I.","year":"2004","unstructured":"McFarlane S.I.; Muniyappa R.; Shin J.J.; Bahtiyar G.; Sowers J.R.; Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 2004,23(1),1-10","journal-title":"Endocrine"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cytogfr.2013.06.001","volume":"24","author":"Baud\u2019huin M.","year":"2013","unstructured":"Baud\u2019huin M.; Duplomb L.; Teletchea S.; Lamoureux F.; Ruiz-Velasco C.; Maillasson M.; Redini F.; Heymann M.F.; Heymann D.; Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013,24(5),401-409","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1359\/jbmr.2000.15.12.2293","volume":"15","author":"Riggs B.L.","year":"2000","unstructured":"Riggs B.L.; Baron R.; Boyle W.J.; Drezner M.; Manolagas S.; Martin T.J.; Stewart A.F.; Suda T.; Yasuda H.; Aubin J.; Goltzman D.; Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J Bone Miner Res 2000,15(12),2293-2296","journal-title":"J Bone Miner Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"Simonet W.S.","year":"1997","unstructured":"Simonet W.S.; Lacey D.L.; Dunstan C.R.; Kelley M.; Chang M.S.; L&#xFC;thy R.; Nguyen H.Q.; Wooden S.; Bennett L.; Boone T.; Shimamoto G.; DeRose M.; Elliott R.; Colombero A.; Tan H.L.; Trail G.; Sullivan J.; Davy E.; Bucay N.; Renshaw-Gegg L.; Hughes T.M.; Hill D.; Pattison W.; Campbell P.; Sander S.; Van G.; Tarpley J.; Derby P.; Lee R.; Boyle W.J.; Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997,89(2),309-319","journal-title":"Cell"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1074\/jbc.273.9.5117","volume":"273","author":"Yamaguchi K.","year":"1998","unstructured":"Yamaguchi K.; Kinosaki M.; Goto M.; Kobayashi F.; Tsuda E.; Morinaga T.; Higashio K.; Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998,273(9),5117-5123","journal-title":"J Biol Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"Emery J.G.","year":"1998","unstructured":"Emery J.G.; McDonnell P.; Burke M.B.; Deen K.C.; Lyn S.; Silverman C.; Dul E.; Appelbaum E.R.; Eichman C.; DiPrinzio R.; Dodds R.A.; James I.E.; Rosenberg M.; Lee J.C.; Young P.R.; Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998,273(23),14363-14367","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"Wiley S.R.","year":"1995","unstructured":"Wiley S.R.; Schooley K.; Smolak P.J.; Din W.S.; Huang C.P.; Nicholl J.K.; Sutherland G.R.; Smith T.D.; Rauch C.; Smith C.A.; Goodwin R.G.; Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995,3(6),673-682","journal-title":"Immunity"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"Pitti R.M.","year":"1996","unstructured":"Pitti R.M.; Marsters S.A.; Ruppert S.; Donahue C.J.; Moore A.; Ashkenazi A.; Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996,271(22),12687-12690","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/cdd.2013.28","volume":"20","author":"Azijli K.","year":"2013","unstructured":"Azijli K.; Weyhenmeyer B.; Peters G.J.; de Jong S.; Kruyt F.A.; Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 2013,20(7),858-868","journal-title":"Cell Death Differ"},{"key":"ref=19","year":"2019","unstructured":"National Cancer Institute2019 https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/denosumab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/01.RES.0000249379.55535.21","volume":"99","author":"Johnson R.C.","year":"2006","unstructured":"Johnson R.C.; Leopold J.A.; Loscalzo J.; Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006,99(10),1044-1059","journal-title":"Circ Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1172\/JCI116391","volume":"91","author":"Bostr&#xF6;m K.","year":"1993","unstructured":"Bostr&#xF6;m K.; Watson K.E.; Horn S.; Wortham C.; Herman I.M.; Demer L.L.; Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993,91(4),1800-1809","journal-title":"J Clin Invest"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1189\/jlb.0403170","volume":"74","author":"Kuwana M.","year":"2003","unstructured":"Kuwana M.; Okazaki Y.; Kodama H.; Izumi K.; Yasuoka H.; Ogawa Y.; Kawakami Y.; Ikeda Y.; Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003,74(5),833-845","journal-title":"J Leukoc Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.yjmcc.2005.03.019","volume":"39","author":"Tintut Y.","year":"2005","unstructured":"Tintut Y.; Abedin M.; Cho J.; Choe A.; Lim J.; Demer L.L.; Regulation of RANKL-induced osteoclastic differentiation by vascular cells. J Mol Cell Cardiol 2005,39(2),389-393","journal-title":"J Mol Cell Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<37:AID-JCP4>3.0.CO;2-M","volume":"184","author":"Dorai H.","year":"2000","unstructured":"Dorai H.; Vukicevic S.; Sampath T.K.; Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000,184(1),37-45","journal-title":"J Cell Physiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1074\/jbc.275.3.2063","volume":"275","author":"Sirard C.","year":"2000","unstructured":"Sirard C.; Kim S.; Mirtsos C.; Tadich P.; Hoodless P.A.; Iti&#xE9; A.; Maxson R.; Wrana J.L.; Mak T.W.; Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling. J Biol Chem 2000,275(3),2063-2070","journal-title":"J Biol Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","volume":"108","author":"Nakashima K.","year":"2002","unstructured":"Nakashima K.; Zhou X.; Kunkel G.; Zhang Z.; Deng J.M.; Behringer R.R.; de Crombrugghe B.; The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002,108(1),17-29","journal-title":"Cell"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"S300","DOI":"10.1097\/01.ASN.0000081663.52165.66","volume":"14","author":"Giachelli C.M.","year":"2003","unstructured":"Giachelli C.M.; Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003,14(9)(Suppl. 4),S300-S304","journal-title":"J Am Soc Nephrol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/01.RES.0000216409.20863.e7","volume":"98","author":"Li X.","year":"2006","unstructured":"Li X.; Yang H.Y.; Giachelli C.M.; Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006,98(7),905-912","journal-title":"Circ Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2174\/156652406778018653","volume":"6","author":"Dellegrottaglie S.","year":"2006","unstructured":"Dellegrottaglie S.; Sanz J.; Rajagopalan S.; Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med 2006,6(5),515-524","journal-title":"Curr Mol Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1093\/ndt\/gfr591","volume":"26","author":"Cannata-Andia J.B.","year":"2011","unstructured":"Cannata-Andia J.B.; Roman-Garcia P.; Hruska K.; The connections between vascular calcification and bone health. Nephrol Dial Transplant 2011,26(11),3429-3436","journal-title":"Nephrol Dial Transplant"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/j.1582-4934.2010.01139.x","volume":"14","author":"Rennenberg R.J.M.W.","year":"2010","unstructured":"Rennenberg R.J.M.W.; Schurgers L.J.; Kroon A.A.; Stehouwer C.D.A.; Arterial calcifications. J Cell Mol Med 2010,14(9),2203-2210","journal-title":"J Cell Mol Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5312\/wjo.v4.i4.186","volume":"4","author":"Martin T.J.","year":"2013","unstructured":"Martin T.J.; Historically significant events in the discovery of RANK\/RANKL\/OPG. World J Orthop 2013,4(4),186-197","journal-title":"World J Orthop"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/CIRCRESAHA.108.189001","volume":"104","author":"Panizo S.","year":"2009","unstructured":"Panizo S.; Cardus A.; Encinas M.; Parisi E.; Valcheva P.; L&#xF3;pez-Ongil S.; Coll B.; Fernandez E.; Valdivielso J.M.; RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009,104(9),1041-1048","journal-title":"Circ Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1159\/000341216","volume":"49","author":"Deuell K.A.","year":"2012","unstructured":"Deuell K.A.; Callegari A.; Giachelli C.M.; Rosenfeld M.E.; Scatena M.; RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-&#x3B1;. J Vasc Res 2012,49(6),510-521","journal-title":"J Vasc Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","volume":"36","author":"Kaden J.J.","year":"2004","unstructured":"Kaden J.J.; Bickelhaupt S.; Grobholz R.; Haase K.K.; Sariko&#xE7; A.; Kili&#xE7; R.; Brueckmann M.; Lang S.; Zahn I.; Vahl C.; Hagl S.; Dempfle C.E.; Borggrefe M.; Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004,36(1),57-66","journal-title":"J Mol Cell Cardiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.107.707380","volume":"117","author":"Morony S.","year":"2008","unstructured":"Morony S.; Tintut Y.; Zhang Z.; Cattley R.C.; Van G.; Dwyer D.; Stolina M.; Kostenuik P.J.; Demer L.L.; Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-\/-) mice. Circulation 2008,117(3),411-420","journal-title":"Circulation"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.vph.2016.07.003","volume":"86","author":"Vassalle C.","year":"2016","unstructured":"Vassalle C.; Mazzone A.; Bone loss and vascular calcification: a bi-directional interplay? Vascul Pharmacol 2016,86,77-86","journal-title":"Vascul Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3233\/BMR-160700","volume":"29","author":"Chen Z.","year":"2016","unstructured":"Chen Z.; Yu Y.; Aortic calcification was associated with risk of fractures: a meta-analysis. J Back Musculoskelet Rehabil 2016,29(4),635-642","journal-title":"J Back Musculoskelet Rehabil"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bone.2009.09.006","volume":"46","author":"Rom&#xE1;n-Garc&#xED;a P.","year":"2010","unstructured":"Rom&#xE1;n-Garc&#xED;a P.; Carrillo-L&#xF3;pez N.; Fern&#xE1;ndez-Mart&#xED;n J.L.; Naves-D&#xED;az M.; Ruiz-Torres M.P.; Cannata-And&#xED;a J.B.; High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010,46(1),121-128","journal-title":"Bone"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/01.RES.87.11.1055","volume":"87","author":"Proudfoot D.","year":"2000","unstructured":"Proudfoot D.; Skepper J.N.; Hegyi L.; Bennett M.R.; Shanahan C.M.; Weissberg P.L.; Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000,87(11),1055-1062","journal-title":"Circ Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bone.2013.08.021","volume":"57","author":"Marulanda J.","year":"2013","unstructured":"Marulanda J.; Gao C.; Roman H.; Henderson J.E.; Murshed M.; Prevention of arterial calcification corrects the low bone mass phenotype in MGP-deficient mice. Bone 2013,57(2),499-508","journal-title":"Bone"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jcp.20354","volume":"204","author":"Zannettino A.C.","year":"2005","unstructured":"Zannettino A.C.; Holding C.A.; Diamond P.; Atkins G.J.; Kostakis P.; Farrugia A.; Gamble J.; To L.B.; Findlay D.M.; Haynes D.R.; Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005,204(2),714-723","journal-title":"J Cell Physiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/j.1538-7836.2007.02681.x","volume":"5","author":"Shahbazi S.","year":"2007","unstructured":"Shahbazi S.; Lenting P.J.; Fribourg C.; Terraube V.; Denis C.V.; Christophe O.D.; Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost 2007,5(9),1956-1962","journal-title":"J Thromb Haemost"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000486787","volume":"55","author":"Davenport C.","year":"2018","unstructured":"Davenport C.; Harper E.; Rochfort K.D.; Forde H.; Smith D.; Cummins P.M.; RANKL inhibits the production of osteoprotegerin from smooth muscle cells under basal conditions and following exposure to cyclic strain. J Vasc Res 2018,55(2),111-123","journal-title":"J Vasc Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1161\/ATVBAHA.109.188185","volume":"29","author":"Ovchinnikova O.","year":"2009","unstructured":"Ovchinnikova O.; Gylfe A.; Bailey L.; Nordstr&#xF6;m A.; Rudling M.; Jung C.; Bergstr&#xF6;m S.; Waldenstr&#xF6;m A.; Hansson G.K.; Nordstr&#xF6;m P.; Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol 2009,29(10),1478-1480","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-004-1652-8","volume":"48","author":"Olesen P.","year":"2005","unstructured":"Olesen P.; Ledet T.; Rasmussen L.M.; Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005,48(3),561-568","journal-title":"Diabetologia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","volume":"26","author":"Bennett B.J.","year":"2006","unstructured":"Bennett B.J.; Scatena M.; Kirk E.A.; Rattazzi M.; Varon R.M.; Averill M.; Schwartz S.M.; Giachelli C.M.; Rosenfeld M.E.; Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-\/- mice. Arterioscler Thromb Vasc Biol 2006,26(9),2117-2124","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"Bucay N.","year":"1998","unstructured":"Bucay N.; Sarosi I.; Dunstan C.R.; Morony S.; Tarpley J.; Capparelli C.; Scully S.; Tan H.L.; Xu W.; Lacey D.L.; Boyle W.J.; Simonet W.S.; Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998,12(9),1260-1268","journal-title":"Genes Dev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1161\/hq1001.097102","volume":"21","author":"Price P.A.","year":"2001","unstructured":"Price P.A.; June H.H.; Buckley J.R.; Williamson M.K.; Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001,21(10),1610-1616","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065201","volume":"8","author":"Weiss R.M.","year":"2013","unstructured":"Weiss R.M.; Lund D.D.; Chu Y.; Brooks R.M.; Zimmerman K.A.; El Accaoui R.; Davis M.K.; Hajj G.P.; Zimmerman M.B.; Heistad D.D.; Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice. PLoS One 2013,8(6)","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/j.1538-7836.2010.03990.x","volume":"8","author":"Vik A.","year":"2010","unstructured":"Vik A.; Mathiesen E.B.; Brox J.; Wilsgaard T.; Nj&#xF8;lstad I.; J&#xF8;rgensen L.; Hansen J.B.; Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Troms&#xF8; study. J Thromb Haemost 2010,8(10),2133-2139","journal-title":"J Thromb Haemost"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/hrt.2010.206714","volume":"97","author":"Andersen G.&#xD8;.","year":"2011","unstructured":"Andersen G.&#xD8;.; Knudsen E.C.; Aukrust P.; Yndestad A.; Oie E.; M&#xFC;ller C.; Seljeflot I.; Ueland T.; Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011,97(6),460-465","journal-title":"Heart"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MCA.0b013e328363242e","volume":"24","author":"L&#xF8;gstrup B.B.","year":"2013","unstructured":"L&#xF8;gstrup B.B.; H&#xF8;fsten D.E.; Christophersen T.B.; M&#xF8;ller J.E.; Bjerre M.; Flyvbjerg A.; B&#xF8;tker H.E.; Egstrup K.; Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction. Coron Artery Dis 2013,24(6),487-492","journal-title":"Coron Artery Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.20471\/acc.2017.56.04.22","volume":"56","author":"Makarovi\u0107 S.","year":"2017","unstructured":"Makarovi\u0107 S.; Makarovi\u0107 Z.; Bili\u0107-\u0106ur&#x10D;i\u0107 I.; Milas-Ahi\u0107 J.; Mihaljevi\u0107 I.; Franceschi M.; Juki\u0107 T.; Serum osteoprotegerin in patients with calcified aortic valve stenosis in relation to heart failure. Acta Clin Croat 2017,56(4),733-741","journal-title":"Acta Clin Croat"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCHEARTFAILURE.110.957332","volume":"4","author":"Ueland T.","year":"2011","unstructured":"Ueland T.; Dahl C.P.; Kjekshus J.; Hulthe J.; B&#xF6;hm M.; Mach F.; Goudev A.; Lindberg M.; Wikstrand J.; Aukrust P.; Gullestad L.; Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011,4(2),145-152","journal-title":"Circ Heart Fail"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00365513.2014.930510","volume":"74","author":"Bjerre M.","year":"2014","unstructured":"Bjerre M.; Hilden J.; Kastrup J.; Skoog M.; Hansen J.F.; Kolmos H.J.; Jensen G.B.; Kj&#xF8;ller E.; Winkel P.; Flyvbjerg A.; Gluud C.; Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. Scand J Clin Lab Invest 2014,74(8),657-664","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/heartjnl-2012-302240","volume":"99","author":"Mogelvang R.","year":"2013","unstructured":"Mogelvang R.; Haahr-Pedersen S.; Bjerre M.; Frystyk J.; Iversen A.; Galatius S.; Flyvbjerg A.; Jensen J.S.; Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013,99(2),106-110","journal-title":"Heart"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/HYPERTENSIONAHA.107.087742","volume":"49","author":"Omland T.","year":"2007","unstructured":"Omland T.; Drazner M.H.; Ueland T.; Abedin M.; Murphy S.A.; Aukrust P.; de Lemos J.A.; Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007,49(6),1392-1398","journal-title":"Hypertension"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","volume":"26","author":"Sandberg W.J.","year":"2006","unstructured":"Sandberg W.J.; Yndestad A.; &#xD8;ie E.; Smith C.; Ueland T.; Ovchinnikova O.; Robertson A.K.; M&#xFC;ller F.; Semb A.G.; Scholz H.; Andreassen A.K.; Gullestad L.; Dam&#xE5;s J.K.; Fr&#xF8;land S.S.; Hansson G.K.; Halvorsen B.; Aukrust P.; Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006,26(4),857-863","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/01.STR.0000129790.00318.a3","volume":"35","author":"Golledge J.","year":"2004","unstructured":"Golledge J.; McCann M.; Mangan S.; Lam A.; Karan M.; Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004,35(7),1636-1641","journal-title":"Stroke"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/ATVBAHA.109.184101","volume":"29","author":"Semb A.G.","year":"2009","unstructured":"Semb A.G.; Ueland T.; Aukrust P.; Wareham N.J.; Luben R.; Gullestad L.; Kastelein J.J.; Khaw K.T.; Boekholdt S.M.; Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol 2009,29(6),975-980","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183910]","volume":"12","author":"Tschiderer L.J.","year":"2017","unstructured":"Tschiderer L.J.; Willeit J.; Schett G.; Kiechl S.; Willeit P.; Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: literature-based meta-analysis involving 26,442 participants. PLoS One 2017,12(8)","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009012","volume":"7","author":"Tschiderer L.","year":"2018","unstructured":"Tschiderer L.; Klingenschmid G.; Nagrani R.; Willeit J.; Laukkanen J.A.; Schett G.; Kiechl S.; Willeit P.; Osteoprotegerin and cardiovascular events in high-risk populations: meta-analysis of 19 prospective studies involving 27450 participants. J Am Heart Assoc 2018,7(16)","journal-title":"J Am Heart Assoc"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.12659\/MSM.895434","volume":"22","author":"Song D.H.","year":"2016","unstructured":"Song D.H.; Zhou P.Z.; Xiu X.L.; Zhou G.H.; Sun Y.X.; Song C.; Relationships of OPG genetic polymorphisms with susceptibility to cardiovascular disease: a meta-analysis. Med Sci Monit 2016,22,1223-1231","journal-title":"Med Sci Monit"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/bmm-2018-0458","volume":"13","author":"Lin J-F.","year":"2019","unstructured":"Lin J-F.; Wu S.; Juang J-M.J.; Chiang F-T.; Hsu L-A.; Teng M-S.; Cheng S-T.; Huang H-L.; Ko Y-L.; Osteoprotegerin and osteopontin levels, but not gene polymorphisms, predict mortality in cardiovascular diseases. Biomark Med 2019,13(9),751-760","journal-title":"Biomark Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10456-008-9127-z","volume":"12","author":"McGonigle J.S.","year":"2009","unstructured":"McGonigle J.S.; Giachelli C.M.; Scatena M.; Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009,12(1),35-46","journal-title":"Angiogenesis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0609.2010.01446.x","volume":"85","author":"Kobayashi-Sakamoto M.","year":"2010","unstructured":"Kobayashi-Sakamoto M.; Isogai E.; Holen I.; Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol 2010,85(1),26-35","journal-title":"Eur J Haematol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1091\/mbc.e04-01-0059","volume":"15","author":"Pritzker L.B.","year":"2004","unstructured":"Pritzker L.B.; Scatena M.; Giachelli C.M.; The role of osteoprotegerin and TNF-related apoptosis inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 2004,15,2834-2841","journal-title":"Mol Biol Cell"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cardiores.2007.07.017","volume":"76","author":"Mangan S.H.","year":"2007","unstructured":"Mangan S.H.; Campenhout A.V.; Rush C.; Golledge J.; Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-&#x3B1; associated with induction of angiopoietin-2. Cardiovasc Res 2007,76(3),494-505","journal-title":"Cardiovasc Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2007-01-068395","volume":"110","author":"Zauli G.","year":"2007","unstructured":"Zauli G.; Corallini F.; Bossi F.; Fischetti F.; Durigutto P.; Celeghini C.; Tedesco F.; Secchiero P.; Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007,110(2),536-543","journal-title":"Blood"},{"key":"ref=71","author":"Cartland S.P.","year":"2019","unstructured":"Cartland S.P.; Genner S.W.; Mart&#xED;nez G.J.; Robertson S.; Kockx M.; Lin R.C.; O'Sullivan J.F.; Koay Y.C.; Cholan P.M.; Kebede M.A.; Murphy A.J.; Masters S.; Bennett M.R.; Jessup W.; Kritharides L.; Geczy C.; Patel S.; Kavurma M.M.;  2019"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2011.05.019","volume":"218","author":"Toffoli B.","year":"2011","unstructured":"Toffoli B.; Pickering R.J.; Tsorotes D.; Wang B.; Bernardi S.; Kantharidis P.; Fabris B.; Zauli G.; Secchiero P.; Thomas M.C.; Osteoprotegerin promotes vascular fibrosis via a TGF-&#x3B2;1 autocrine loop. Atherosclerosis 2011,218(1),61-68","journal-title":"Atherosclerosis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.cyto.2012.02.004","volume":"58","author":"Heymann M.F.","year":"2012","unstructured":"Heymann M.F.; Herisson F.; Davaine J.M.; Charrier C.; Battaglia S.; Passuti N.; Lambert G.; Gou&#xEB;ffic Y.; Heymann D.; Role of the OPG\/RANK\/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine 2012,58(2),300-306","journal-title":"Cytokine"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1084\/jem.20051062","volume":"203","author":"Sato K.","year":"2006","unstructured":"Sato K.; Niessner A.; Kopecky S.L.; Frye R.L.; Goronzy J.J.; Weyand C.M.; TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006,203(1),239-250","journal-title":"J Exp Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000358920]","volume":"51","author":"Callegari A.","year":"2014","unstructured":"Callegari A.; Coons M.L.; Ricks J.L.; Rosenfeld M.E.; Scatena M.; Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-&#x3BA;B ligand and interleukin 6. J Vasc Res 2014,51(2),118-131","journal-title":"J Vasc Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.4049\/jimmunol.166.3.1482","volume":"166","author":"Yun T.J.","year":"2001","unstructured":"Yun T.J.; Tallquist M.D.; Aicher A.; Rafferty K.L.; Marshall A.J.; Moon J.J.; Ewings M.E.; Mohaupt M.; Herring S.W.; Clark E.A.; Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001,166(3),1482-1491","journal-title":"J Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/cvr\/cvr084","volume":"91","author":"Di Bartolo B.A.","year":"2011","unstructured":"Di Bartolo B.A.; Schoppet M.; Mattar M.Z.; Rachner T.D.; Shanahan C.M.; Kavurma M.M.; Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 2011,91(3),537-545","journal-title":"Cardiovasc Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/01.ATV.0000133194.94939.42","volume":"24","author":"Abedin M.","year":"2004","unstructured":"Abedin M.; Tintut Y.; Demer L.L.; Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004,24(7),1161-1170","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/564934","volume":"2015","author":"de Ciriza C.P.","year":"2015","unstructured":"de Ciriza C.P.; Lawrie A.; Varo N.; Osteoprotegerin in cardiometabolic disorders. Int J Endocrinol 2015,2015","journal-title":"Int J Endocrinol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.106.643841","volume":"114","author":"Secchiero P.","year":"2006","unstructured":"Secchiero P.; Candido R.; Corallini F.; Zacchigna S.; Toffoli B.; Rimondi E.; Fabris B.; Giacca M.; Zauli G.; Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006,114(14),1522-1530","journal-title":"Circulation"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1074\/jbc.M706927200","volume":"283","author":"Kavurma M.M.","year":"2008","unstructured":"Kavurma M.M.; Schoppet M.; Bobryshev Y.V.; Khachigian L.M.; Bennett M.R.; TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem 2008,283(12),7754-7762","journal-title":"J Biol Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1161\/01.CIR.0000062702.60708.C4","volume":"107","author":"Secchiero P.","year":"2003","unstructured":"Secchiero P.; Gonelli A.; Carnevale E.; Milani D.; Pandolfi A.; Zella D.; Zauli G.; TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003,107(17),2250-2256","journal-title":"Circulation"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.clinbiochem.2014.05.006","volume":"47","author":"P&#xE9;rez de Ciriza C.","year":"2014","unstructured":"P&#xE9;rez de Ciriza C.; Lawrie A.; Varo N.; Influence of pre-analytical and analytical factors on osteoprotegerin measurements. Clin Biochem 2014,47(13-14),1279-1285","journal-title":"Clin Biochem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2008.03.026","volume":"201","author":"Nybo M.","year":"2008","unstructured":"Nybo M.; Rasmussen L.M.; Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 2008,201(1),33-35","journal-title":"Atherosclerosis"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1160\/TH06-11-0671","volume":"98","author":"Vik A.","year":"2007","unstructured":"Vik A.; Brodin E.; Sveinbj&#xF8;rnsson B.; Hansen J.B.; Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 2007,98(1),148-154","journal-title":"Thromb Haemost"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/jbmr.3213","volume":"32","author":"Szulc P.","year":"2017","unstructured":"Szulc P.; Chapurlat R.; Hofbauer L.C.; Prediction of fractures and major cardiovascular events in men using serum osteoprotegerin levels: the prospective STRAMBO study. J Bone Miner Res 2017,32(11),2288-2296","journal-title":"J Bone Miner Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","volume":"109","author":"Kiechl S.","year":"2004","unstructured":"Kiechl S.; Schett G.; Wenning G.; Redlich K.; Oberhollenzer M.; Mayr A.; Santer P.; Smolen J.; Poewe W.; Willeit J.; Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004,109(18),2175-2180","journal-title":"Circulation"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fcvm.2018.00196","volume":"5","author":"B&#xE4;ck M.","year":"2019","unstructured":"B&#xE4;ck M.; Aranyi T.; Cancela M.L.; Carracedo M.; Concei&#xE7;&#xE3;o N.; Leftheriotis G.; Macrae V.; Martin L.; Nitschke Y.; Pasch A.; Quaglino D.; Rutsch F.; Shanahan C.; Sorribas V.; Szeri F.; Valdivielso P.; Vanakker O.; Kempf H.; Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet. Front Cardiovasc Med 2019,5,196","journal-title":"Front Cardiovasc Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1167\/iovs.16-20993","volume":"58","author":"Abu El-Asrar A.M.","year":"2017","unstructured":"Abu El-Asrar A.M.; Struyf S.; Mohammad G.; Gouwy M.; Rytinx P.; Siddiquei M.M.; Hern&#xE1;ndez C.; Alam K.; Mousa A.; De Hertogh G.; Opdenakker G.; Sim&#xF3; R.; Osteoprotegerin is a new regulator of inflammation and angiogenesis in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2017,58(7),3189-3201","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1024\/0301-1526\/a000682","volume":"47","author":"Demkov&#xE1; K.","year":"2018","unstructured":"Demkov&#xE1; K.; Koz&#xE1;rov&#xE1; M.; Malachovsk&#xE1; Z.; Javorsk&#xFD; M.; Tk&#xE1;&#x10D; I.; Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus. Vasa 2018,47(2),131-135","journal-title":"Vasa"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00592-017-1065-z","volume":"55","author":"Daniele G.","year":"2018","unstructured":"Daniele G.; Winnier D.; Mari A.; Bruder J.; Fourcaudot M.; Pengou Z.; Hansis-Diarte A.; Jenkinson C.; Tripathy D.; Folli F.; The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetol 2018,55(2),139-148","journal-title":"Acta Diabetol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-017-0581-z","volume":"16","author":"Giovannini S.","year":"2017","unstructured":"Giovannini S.; Tinelli G.; Biscetti F.; Straface G.; Angelini F.; Pitocco D.; Mucci L.; Landolfi R.; Flex A.; Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovasc Diabetol 2017,16(1),99","journal-title":"Cardiovasc Diabetol"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e322","volume":"33","author":"Chae S.Y.","year":"2018","unstructured":"Chae S.Y.; Chung W.; Kim Y.H.; Oh Y.K.; Lee J.; Choi K.H.; Ahn C.; Kim Y.S.; The correlation of serum osteoprotegerin with non-traditional cardiovascular risk factors and arterial stiffness in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study. J Korean Med Sci 2018,33(53)","journal-title":"J Korean Med Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/pedi.12379","volume":"18","author":"Fekih O.","year":"2017","unstructured":"Fekih O.; Triki H.; Triki S.; Neffati F.; Chouchane S.; Guediche M.N.; Najjar M.F.; Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes. Pediatr Diabetes 2017,18(3),230-236","journal-title":"Pediatr Diabetes"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2018.01.011","volume":"270","author":"Bozic M.","year":"2018","unstructured":"Bozic M.; M&#xE9;ndez-Barbero N.; Guti&#xE9;rrez-Mu&#xF1;oz C.; Betriu A.; Egido J.; Fern&#xE1;ndez E.; Mart&#xED;n-Ventura J.L.; Valdivielso. J.M.; Blanco-Colio, L.M. Investigators from the NEFRONA study. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Atherosclerosis 2018,270,13-20","journal-title":"Atherosclerosis"},{"key":"ref=96","first-page":"153","volume":"24","author":"Elsaeed A.M.","year":"2017","unstructured":"Elsaeed A.M.; Ibrahiem A.H.; Ali A.A.; Matrix metalloproteinase 2 and osteoprotegrin as new markers of increased atherosclerotic risk in Egyptian patients with chronic kidney disease. Egypt J Immunol 2017,24(1),153-164","journal-title":"Egypt J Immunol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12882-017-0701-8","volume":"18","author":"Collado S.","year":"2017","unstructured":"Collado S.; Coll E.; Nicolau C.; Azqueta M.; Pons M.; Cruzado J.M.; de la Torre B.; Deulofeu R.; Mojal S.; Pascual J.; Cases A.; Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol 2017,18(1),290","journal-title":"BMC Nephrol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2016.08.010","volume":"253","author":"Nakahara T.","year":"2016","unstructured":"Nakahara T.; Kawai-Kowase K.; Matsui H.; Sunaga H.; Utsugi T.; Iso T.; Arai M.; Tomono S.; Kurabayashi M.; Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis 2016,253,102-110","journal-title":"Atherosclerosis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.semnephrol.2014.09.005","volume":"34","author":"Olauson H.","year":"2014","unstructured":"Olauson H.; Vervloet M.G.; Cozzolino M.; Massy Z.A.; Torres P.U.; Larsson T.E.; New insights into the FGF23-Klotho axis. Semin Nephrol 2014,34(6),586-597","journal-title":"Semin Nephrol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fendo.2018.00351","volume":"9","author":"St&#xF6;hr R.","year":"2018","unstructured":"St&#xF6;hr R.; Schuh A.; Heine G.H.; Brandenburg V.; FGF23 in cardiovascular disease: innocent bystander or active mediator? Front Endocrinol (Lausanne) 2018,9,351","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","volume":"20","author":"Beckwitt C.H.","year":"2018","unstructured":"Beckwitt C.H.; Brufsky A.; Oltvai Z.N.; Wells A.; Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res 2018,20(1),144","journal-title":"Breast Cancer Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","volume":"33","author":"Endo A.","year":"1992","unstructured":"Endo A.; The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992,33(11),1569-1582","journal-title":"J Lipid Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/CE.S8008","volume":"5","author":"Alagona P.","year":"2010","unstructured":"Alagona P.; Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid 2010,5,91-105","journal-title":"Core Evid"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCRESAHA.108.192500","volume":"104","author":"Bolli R.","year":"2009","unstructured":"Bolli R.; Dawn B.; The cornucopia of &#x201C;pleiotropic&#x201D; actions of statins: myogenesis as a new mechanism for statin-induced benefits? Circ Res 2009,104(2),144-146","journal-title":"Circ Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/138161209787315684","volume":"15","author":"Zhou Q.","year":"2009","unstructured":"Zhou Q.; Liao J.K.; Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009,15(5),467-478","journal-title":"Curr Pharm Des"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1001\/jama.283.24.3205","volume":"283","author":"Meier C.R.","year":"2000","unstructured":"Meier C.R.; Schlienger R.G.; Kraenzlin M.E.; Schlegel B.; Jick H.; HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000,283(24),3205-3210","journal-title":"JAMA"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1001\/jama.283.24.3211","volume":"283","author":"Wang P.S.","year":"2000","unstructured":"Wang P.S.; Solomon D.H.; Mogun H.; Avorn J.; HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000,283(24),3211-3216","journal-title":"JAMA"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","volume":"286","author":"Mundy G.","year":"1999","unstructured":"Mundy G.; Garrett R.; Harris S.; Chan J.; Chen D.; Rossini G.; Boyce B.; Zhao M.; Gutierrez G.; Stimulation of bone formation in vitro and in rodents by statins. Science 1999,286(5446),1946-1949","journal-title":"Science"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1592\/phco.25.2.228.56954","volume":"25","author":"Gonyeau M.J.","year":"2005","unstructured":"Gonyeau M.J.; Statins and osteoporosis: a clinical review. Pharmacotherapy 2005,25(2),228-243","journal-title":"Pharmacotherapy"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jcb.21259","volume":"101","author":"Ruiz-Gaspa S.","year":"2007","unstructured":"Ruiz-Gaspa S.; Nogues X.; Enjuanes A.; Monllau J.C.; Blanch J.; Carreras R.; Mellibovsky L.; Grinberg D.; Balcells S.; D&#xED;ez-Perez A.; Pedro-Botet J.; Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem 2007,101(6),1430-1438","journal-title":"J Cell Biochem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/jbmr.163","volume":"25","author":"Pagkalos J.","year":"2010","unstructured":"Pagkalos J.; Cha J.M.; Kang Y.; Heliotis M.; Tsiridis E.; Mantalaris A.; Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 2010,25(11),2470-2478","journal-title":"J Bone Miner Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1359\/jbmr.080603","volume":"23","author":"Gutierrez G.E.","year":"2008","unstructured":"Gutierrez G.E.; Edwards J.R.; Garrett I.R.; Nyman J.S.; McCluskey B.; Rossini G.; Flores A.; Neidre D.B.; Mundy G.R.; Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res 2008,23(11),1722-1730","journal-title":"J Bone Miner Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/DDDT.S133020","volume":"11","author":"El-Nabarawi N.","year":"2017","unstructured":"El-Nabarawi N.; El-Wakd M.; Salem M.; Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug Des Devel Ther 2017,11,1383-1391","journal-title":"Drug Des Devel Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1210\/en.2011-0016","volume":"152","author":"Weivoda M.M.","year":"2011","unstructured":"Weivoda M.M.; Hohl R.J.; Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology 2011,152(8),3113-3122","journal-title":"Endocrinology"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4161\/sgtp.2.3.16453","volume":"2","author":"Itzstein C.","year":"2011","unstructured":"Itzstein C.; Coxon F.P.; Rogers M.J.; The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2011,2(3),117-130","journal-title":"Small GTPases"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/jcb.20074","volume":"92","author":"Maeda T.","year":"2004","unstructured":"Maeda T.; Matsunuma A.; Kurahashi I.; Yanagawa T.; Yoshida H.; Horiuchi N.; Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 2004,92(3),458-471","journal-title":"J Cell Biochem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nutres.2010.03.004","volume":"30","author":"Chen P.Y.","year":"2010","unstructured":"Chen P.Y.; Sun J.S.; Tsuang Y.H.; Chen M.H.; Weng P.W.; Lin F.H.; Simvastatin promotes osteoblast viability and differentiation via Ras\/Smad\/Erk\/BMP-2 signaling pathway. Nutr Res 2010,30(3),191-199","journal-title":"Nutr Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.mce.2012.05.002","volume":"361","author":"Tsubaki M.","year":"2012","unstructured":"Tsubaki M.; Satou T.; Itoh T.; Imano M.; Yanae M.; Kato C.; Takagoshi R.; Komai M.; Nishida S.; Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras\/MEK\/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol 2012,361(1-2),219-231","journal-title":"Mol Cell Endocrinol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3904\/kjim.2015.244","volume":"33","author":"Lee W.S.","year":"2018","unstructured":"Lee W.S.; Lee E.G.; Sung M.S.; Choi Y.J.; Yoo W.H.; Atorvastatin inhibits osteoclast differentiation by suppressing NF-&#x3BA;B and MAPK signaling during IL-1&#x3B2;-induced osteoclastogenesis. Korean J Intern Med (Korean Assoc Intern Med) 2018,33(2),397-406","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3858\/emm.2011.43.11.067","volume":"43","author":"Moon H.J.","year":"2011","unstructured":"Moon H.J.; Kim S.E.; Yun Y.P.; Hwang Y.S.; Bang J.B.; Park J.H.; Kwon I.K.; Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med 2011,43(11),605-612","journal-title":"Exp Mol Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00774-015-0656-4","volume":"33","author":"Callaway D.A.","year":"2015","unstructured":"Callaway D.A.; Jiang J.X.; Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab 2015,33(4),359-370","journal-title":"J Bone Miner Metab"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/01.mca.0000131573.31966.34","volume":"15","author":"Davignon J.","year":"2004","unstructured":"Davignon J.; Jacob R.F.; Mason R.P.; The antioxidant effects of statins. Coron Artery Dis 2004,15(5),251-258","journal-title":"Coron Artery Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/ijc.23745","volume":"123","author":"Ahn K.S.","year":"2008","unstructured":"Ahn K.S.; Sethi G.; Chaturvedi M.M.; Aggarwal B.B.; Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 2008,123(8),1733-1740","journal-title":"Int J Cancer"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdsr.2009.10.003","volume":"46","author":"Jimi E.","year":"2010","unstructured":"Jimi E.; Hirata S.; Shin M.; Yamazaki M.; Fukushima H.; Molecular mechanisms of BMP-induced bone formation: cross-talk between BMP and NF-&#x3BA;B signaling pathways in osteoblastogenesis. Jpn Dent Sci Rev 2010,46(1),33-42","journal-title":"Jpn Dent Sci Rev"},{"key":"ref=125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196713]","volume":"13","author":"Lin T-K.","year":"2018","unstructured":"Lin T-K.; Chou P.; Lin C-H.; Hung Y-J.; Jong G-P.; Long-term effect of statins on the risk of new-onset osteoporosis: a nationwide population-based cohort study. PLoS One 2018,13(5)","journal-title":"PLoS One"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00198-016-3844-8","volume":"28","author":"An T.","year":"2017","unstructured":"An T.; Hao J.; Sun S.; Li R.; Yang M.; Cheng G.; Zou M.; Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2017,28(1),47-57","journal-title":"Osteoporos Int"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003042","volume":"95","author":"Wang Z.","year":"2016","unstructured":"Wang Z.; Li Y.; Zhou F.; Piao Z.; Hao J.; Effects of statins on bone mineral density and fracture risk: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2016,95(22)","journal-title":"Medicine (Baltimore)"},{"key":"ref=128","first-page":"8269","volume":"8","author":"Jin S.","year":"2015","unstructured":"Jin S.; Jiang J.; Bai P.; Zhang M.; Tong X.; Wang H.; Lu Y.; Statin use and risk of fracture: a meta-analysis. Int J Clin Exp Med 2015,8(5),8269-8275","journal-title":"Int J Clin Exp Med"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00198-004-1793-0","volume":"16","author":"Hatzigeorgiou C.","year":"2005","unstructured":"Hatzigeorgiou C.; Jackson J.L.; Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 2005,16(8),990-998","journal-title":"Osteoporos Int"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2013.01.044","volume":"54","author":"Liu J.","year":"2013","unstructured":"Liu J.; Zhu L.P.; Yang X.L.; Huang H.L.; Ye D.Q.; HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis. Bone 2013,54(1),151-156","journal-title":"Bone"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bone.2007.02.019","volume":"40","author":"Uzzan B.","year":"2007","unstructured":"Uzzan B.; Cohen R.; Nicolas P.; Cucherat M.; Perret G.Y.; Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007,40(6),1581-1587","journal-title":"Bone"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/pds.1363","volume":"16","author":"Toh S.","year":"2007","unstructured":"Toh S.; Hern&#xE1;ndez-D&#xED;az S.; Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007,16(6),627-640","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archinte.164.2.146","volume":"164","author":"Bauer D.C.","year":"2004","unstructured":"Bauer D.C.; Mundy G.R.; Jamal S.A.; Black D.M.; Cauley J.A.; Ensrud K.E.; van der Klift M.; Pols H.A.; Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004,164(2),146-152","journal-title":"Arch Intern Med"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(00)04042-3","volume":"357","author":"Reid I.R.","year":"2001","unstructured":"Reid I.R.; Hague W.; Emberson J.; Baker J.; Tonkin A.; Hunt D.; MacMahon S.; Sharpe N.; Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 2001,357(9255),509-512","journal-title":"Lancet"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jamainternmed.2014.6388","volume":"175","author":"Pe&#xF1;a J.M.","year":"2015","unstructured":"Pe&#xF1;a J.M.; Aspberg S.; MacFadyen J.; Glynn R.J.; Solomon D.H.; Ridker P.M.; Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med 2015,175(2),171-177","journal-title":"JAMA Intern Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/jama.284.15.1921]","volume":"284","author":"Pedersen T.R.","year":"2000","unstructured":"Pedersen T.R.; Kjekshus J.; Statin drugs and the risk of fracture. JAMA 2000,284(15),1921-1922","journal-title":"JAMA"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1001\/archinte.160.18.2865","volume":"160","author":"Wada Y.","year":"2000","unstructured":"Wada Y.; Nakamura Y.; Koshiyama H.; Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 2000,160(18),2865","journal-title":"Arch Intern Med"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/jpp.58.1.0002","volume":"58","author":"Jadhav S.B.","year":"2006","unstructured":"Jadhav S.B.; Jain G.K.; Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006,58(1),3-18","journal-title":"J Pharm Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1210\/en.2002-220682","volume":"144","author":"Maeda T.","year":"2003","unstructured":"Maeda T.; Kawane T.; Horiuchi N.; Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003,144(2),681-692","journal-title":"Endocrinology"},{"key":"ref=140","doi-asserted-by":"publisher","DOI":"10.1159\/000322332","author":"Monjo M.","year":"2010","unstructured":"Monjo M.; Rubert M.; Ellingsen J.E.; Lyngstadaas S.P.;  Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells 2010","journal-title":"Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/178581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178581\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/178581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T13:57:37Z","timestamp":1643291857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178581\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":140,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200123151132","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}